Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial

S-CitAD Research Group

doi:10.1016/j.jalz.2019.06.4946

Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial

S-CitAD Research Group

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Introduction: Alzheimer's disease (AD) is a disabling, common cause of dementia, and agitation is one of the most common and distressing symptoms for patients with AD. Escitalopram for agitation in Alzheimer's disease (S-CitAD) tests a novel, clinically derived therapeutic approach to treat agitation in patients with AD. Methods: S-CitAD is a NIH-funded, investigator-initiated, randomized, multicenter clinical trial. Participants receive a structured psychosocial intervention (PSI) as standard of care. Participants without sufficient response to PSI are randomized to receive 15 mg escitalopram/day or a matching placebo in addition to PSI. Primary outcome is the Modified Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (mADCS-CGIC). Discussion: S-CitAD will provide information about a practical, immediately available approach to treating agitation in patients with AD. S-CitAD may become a model of how to evaluate and predict treatment response in patients with AD and agitation as a neuropsychiatric symptom (ClinicalTrials.gov Identifier: NCT03108846).

Original language	English (US)
Pages (from-to)	1427-1436
Number of pages	10
Journal	Alzheimer's and Dementia
Volume	15
Issue number	11
DOIs	https://doi.org/10.1016/j.jalz.2019.06.4946
State	Published - Nov 2019

Keywords

Agitation
Alzheimer dementia
Escitalopram
Neuropsychiatric symptoms
Psychosocial intervention
Randomized trial

ASJC Scopus subject areas

Epidemiology
Health Policy
Developmental Neuroscience
Clinical Neurology
Geriatrics and Gerontology
Cellular and Molecular Neuroscience
Psychiatry and Mental health

Access to Document

10.1016/j.jalz.2019.06.4946

Cite this

@article{458c86d54e604d228ad14077648ab537,

title = "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial",

abstract = "Introduction: Alzheimer's disease (AD) is a disabling, common cause of dementia, and agitation is one of the most common and distressing symptoms for patients with AD. Escitalopram for agitation in Alzheimer's disease (S-CitAD) tests a novel, clinically derived therapeutic approach to treat agitation in patients with AD. Methods: S-CitAD is a NIH-funded, investigator-initiated, randomized, multicenter clinical trial. Participants receive a structured psychosocial intervention (PSI) as standard of care. Participants without sufficient response to PSI are randomized to receive 15 mg escitalopram/day or a matching placebo in addition to PSI. Primary outcome is the Modified Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (mADCS-CGIC). Discussion: S-CitAD will provide information about a practical, immediately available approach to treating agitation in patients with AD. S-CitAD may become a model of how to evaluate and predict treatment response in patients with AD and agitation as a neuropsychiatric symptom (ClinicalTrials.gov Identifier: NCT03108846).",

keywords = "Agitation, Alzheimer dementia, Escitalopram, Neuropsychiatric symptoms, Psychosocial intervention, Randomized trial",

author = "{S-CitAD Research Group} and Stephan Ehrhardt and Porsteinsson, {Anton P.} and Munro, {Cynthia A.} and Rosenberg, {Paul B.} and Pollock, {Bruce G.} and Devanand, {Davangere P.} and Jacobo Mintzer and Rajji, {Tarek K.} and Zahinoor Ismail and Schneider, {Lon S.} and Baksh, {Sheriza N.} and Drye, {Lea T.} and Dimitri Avramopoulos and Shade, {David M.} and Lyketsos, {Constantine G.} and Cynthia Munro and Hochang Lee and Nicholas Bienko and Dave Shade and Jennifer Jones and Casper, {Anne Shanklin} and Constantine Frangakis and Andy Lears and Sheriza Baksh and Jamie Perin and Laurie Ryan and McKelvy, {Alvin D.} and Paul Rosenberg and Milap Nowrangi and Sarah Lawrence and Meghan Schultz and Nimra Jamil and Devanand, {D. P.} and Laura Simon-Pearson and {Pelton Jacobo Mintzer}, Gregory and Olga Brawman-Mintzer and Arthur Williams and Anthony Awkar and Melanie Keltz and Nancy Kowalski and Kaitlyn Lane and Kim Martin and Susan Salem-Spencer and Asa Widman and Sanjeev Kumar and Lillian Lourenco and Mulsant, {Benoit H.} and Kyle Lago and Maurcio Becerra and Karen Dagerman",

note = "Publisher Copyright: {\textcopyright} 2019 the Alzheimer's Association",

year = "2019",

month = nov,

doi = "10.1016/j.jalz.2019.06.4946",

language = "English (US)",

volume = "15",

pages = "1427--1436",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "John Wiley and Sons Inc.",

number = "11",

}

TY - JOUR

T1 - Escitalopram for agitation in Alzheimer's disease (S-CitAD)

T2 - Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial

AU - S-CitAD Research Group

AU - Ehrhardt, Stephan

AU - Porsteinsson, Anton P.

AU - Munro, Cynthia A.

AU - Rosenberg, Paul B.

AU - Pollock, Bruce G.

AU - Devanand, Davangere P.

AU - Mintzer, Jacobo

AU - Rajji, Tarek K.

AU - Ismail, Zahinoor

AU - Schneider, Lon S.

AU - Baksh, Sheriza N.

AU - Drye, Lea T.

AU - Avramopoulos, Dimitri

AU - Shade, David M.

AU - Lyketsos, Constantine G.

AU - Munro, Cynthia

AU - Lee, Hochang

AU - Bienko, Nicholas

AU - Shade, Dave

AU - Jones, Jennifer

AU - Casper, Anne Shanklin

AU - Frangakis, Constantine

AU - Lears, Andy

AU - Baksh, Sheriza

AU - Perin, Jamie

AU - Ryan, Laurie

AU - McKelvy, Alvin D.

AU - Rosenberg, Paul

AU - Nowrangi, Milap

AU - Lawrence, Sarah

AU - Schultz, Meghan

AU - Jamil, Nimra

AU - Devanand, D. P.

AU - Simon-Pearson, Laura

AU - Pelton Jacobo Mintzer, Gregory

AU - Brawman-Mintzer, Olga

AU - Williams, Arthur

AU - Awkar, Anthony

AU - Keltz, Melanie

AU - Kowalski, Nancy

AU - Lane, Kaitlyn

AU - Martin, Kim

AU - Salem-Spencer, Susan

AU - Widman, Asa

AU - Kumar, Sanjeev

AU - Lourenco, Lillian

AU - Mulsant, Benoit H.

AU - Lago, Kyle

AU - Becerra, Maurcio

AU - Dagerman, Karen

PY - 2019/11

Y1 - 2019/11

N2 - Introduction: Alzheimer's disease (AD) is a disabling, common cause of dementia, and agitation is one of the most common and distressing symptoms for patients with AD. Escitalopram for agitation in Alzheimer's disease (S-CitAD) tests a novel, clinically derived therapeutic approach to treat agitation in patients with AD. Methods: S-CitAD is a NIH-funded, investigator-initiated, randomized, multicenter clinical trial. Participants receive a structured psychosocial intervention (PSI) as standard of care. Participants without sufficient response to PSI are randomized to receive 15 mg escitalopram/day or a matching placebo in addition to PSI. Primary outcome is the Modified Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (mADCS-CGIC). Discussion: S-CitAD will provide information about a practical, immediately available approach to treating agitation in patients with AD. S-CitAD may become a model of how to evaluate and predict treatment response in patients with AD and agitation as a neuropsychiatric symptom (ClinicalTrials.gov Identifier: NCT03108846).

AB - Introduction: Alzheimer's disease (AD) is a disabling, common cause of dementia, and agitation is one of the most common and distressing symptoms for patients with AD. Escitalopram for agitation in Alzheimer's disease (S-CitAD) tests a novel, clinically derived therapeutic approach to treat agitation in patients with AD. Methods: S-CitAD is a NIH-funded, investigator-initiated, randomized, multicenter clinical trial. Participants receive a structured psychosocial intervention (PSI) as standard of care. Participants without sufficient response to PSI are randomized to receive 15 mg escitalopram/day or a matching placebo in addition to PSI. Primary outcome is the Modified Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (mADCS-CGIC). Discussion: S-CitAD will provide information about a practical, immediately available approach to treating agitation in patients with AD. S-CitAD may become a model of how to evaluate and predict treatment response in patients with AD and agitation as a neuropsychiatric symptom (ClinicalTrials.gov Identifier: NCT03108846).

KW - Agitation

KW - Alzheimer dementia

KW - Escitalopram

KW - Neuropsychiatric symptoms

KW - Psychosocial intervention

KW - Randomized trial

UR - http://www.scopus.com/inward/record.url?scp=85072777249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072777249&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2019.06.4946

DO - 10.1016/j.jalz.2019.06.4946

M3 - Article

C2 - 31587995

AN - SCOPUS:85072777249

SN - 1552-5260

VL - 15

SP - 1427

EP - 1436

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 11

ER -

Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this